Total: $2,314.04M

Company
(Symbol)#

Type Of
Financing

Number
Of Shares, Units Or Warrants (M)

Amount
Raised
(M)

Investors; Placement Agents; Details (Date)@


Acrongenomics
Inc.
(OTC BB:
AGNM)

Private placement of stock

0.4S

$1

The company sold stock at $2.50 per share; a finder's fee of 10% will be paid in stock (11/19)

Active Biotech
AB
(Sweden;
SSE:ACTI)

Private placement of convertible debentures

N/A

SEK150 (US$21.4)

The loan carries an interest rate of 2% and matures for payment on June 30, 2009; the conversion price is SEK40 per share; MGA Holding AB guaranteed the entire issue (11/9)

American
Oriental
Bioengineering
Inc.
(China;
OTC BB:AOBO)

Private placement of stock and warrants

6S and 9W

$6

The company sold units consisting of one common share at $1, a three-year warrant to purchase one- half of a share exercisable at $1.60, and a three-year warrant to purchase one share at $0.85; Westminster Securities Corp. was placement agent (11/23)

Amgen Inc.
(AMGN)

Private placement of notes

N/A

$2,000

Amgen sold $1B of 4% senior notes due 2009 and $1B of 4.85% senior notes due 2014, raising $2 bil- lion (11/15)

Australian
Cancer
Technology
Ltd.
(Australia;
ASX:ACU)

Rights issue

ND

A$4 (US$3)

The company completed a 1-for-10 rights issue with a sub- underwritten shortfall placed by Burdett Buckeridge Young Ltd. (11/5)

Cell Genesys
Inc.
(CEGE)

Private placement of convertible notes

N/A

$35

Purchasers of $110M in notes in October exercised their option on another $35M of the 3.125% senior notes due 2011, which are convertible into common stock at $9.10 per share (11/17)

Dyadic
International
Inc.
(OTC BB:
DYAD)

Private placement of stock

ND

$25.3

In conjunciton with its reverse merger with CCP Worldwide Inc., Dyadic became a public company and completed a series of financing transactions led by The Pinnacle Fund LP, Mercantile Capital Group, Knott Partners and Crestview Capital Funds; Brean Murray & Co. Inc. and Sanders Morris Harris were placement agents (11/5)

Elite
Pharmaceuticals
Inc.
(AMEX:ELI)

Private placement of preferred stock and warrants

0.517S and 5.17W

$6.6

The Series A preferred shares were sold in three tranches at prices between $12.30 and $14.40; each is convertible into 10 common shares, or 5.17M shares; warrants are convertible into common shares at $1.54 to $1.84 per share; purchasers were S.A.C. Capital Associates LLC, The Marlin Funds, Jess Morgan & Co. and Valor Capital Management LP; Indigo Securities LLC was placement agent (11/4)

Genaera Corp.
(GENR)

Private placement of stock

4.18S

$14.4

The shares were sold from a shelf registration at $3.45 each, a 13% discount to the price when the deal was negotiated; WR Hambrecht + Co. and Fortis Securities were placement agents (11/2)

Genaissance
Pharmaceuticals
Inc.
(GNSC)

Private placement of stock and warrants

3.55S and 3.55W

$6

The warrants are exercisable at $1.69 per share; Legg Mason Wood Walker Inc. was placement agent (11/19)

GeneMedix
plc
(UK; LSE:GMX)

Private placement of stock

2.5S

£0.292 (US$0.54)

The financing completed a total £0.562 investment from funds advised by Southridge Capital Management LLC, which also provided a $10M capital facility (10/20)**

Generex
Biotechnology
Corp.
(GNBT)

Private placement of convertible notes and warrants

N/A

$4

The 6%, 15-month debenture is convertible into stock initially at $0.82 per share, and then at 90% of a 10-day average; the company can repay the note in stock at 90% of a 20-day average; warrants for the same number of shares are exercisable at 110% of the debenture conversion price (11/10)

Geron Corp.
(GERN)

Private placement of stock and warrants

6.5S and 4.3W

$40

The stock was sold to institutional investors from a shelf registration at $6.10 per share; 2M warrants are exercisable for 30 days at that price, and 2.3M warrants are exercisable for 180 days at a premium; the company arranged the financing (11/11)

ImmuneRegen
BioSciences
Inc.
(subsidiary of
IR BioSciences
Holdings Inc.;
OTC BB:IRBO)

Private placement of stock

ND

$2.45

Joseph Stevens & Co. Inc. provided the funding for the wholly owned subsidiary of IR BioSciences (11/2)

Imugene Ltd.
(Australia;
ASX:IMU)

Private placement of stock and warrants

13.48S and 2.7W

A$3.37 (US$2.6)

The shares were placed at A$0.25 each, pre-dominantly with institutional clients of Southern Cross Equities Ltd.; the warrants are exercisable at A$0.50 each; shareholders will vote in January on whether to increase the financing to A$6M (11/23)

Inhibitex Inc.
(INHX)

Private placement of stock and warrants

6.8S and 2W

$50

The stock was sold at $7.34 per share, and the warrants are exercisable at $8.81 per share; Lazard Freres & Co. was placement agent (11/5)

Insmed Inc.
(INSM)

Private placement of stock and warrants

6.5S and 3.25W

$8.7

The stock was sold at $1.35 per share, and the warrants are exercisable at $2 per share; Wells Fargo Securities LLC was placement agent (11/8)

MediGene AG (Germany; FSE:MDG)

Private placement of stock

3.1S

€21.6 (US$28.1)

The company placed the shares at €7 each with existing shareholders and new institutional investors (11/15)

Oragenics Inc. (AMEX:ONI)

Private placement of stock and warrants

0.25S and 0.125W

$0.69

The company sold the shares at $2.75 each; the warrants are exercisable at $3.50 per share (11/30)

Pharming Group
NV
(the Netherlands; Euronext:PHARM)

Private placement of stock

3S

€6 (US$7.97)

The shares were placed through Amsterdams Effectenkantoor BV (11/29)

Resverlogix
Corp.
(Canada;
VSE: RVX)

Private placement of stock

2.64S

C$7.9 (US$6.66)

The shares were sold at C$3 each; First Associates Investments Inc. was lead agent; other agents were Haywood Securities Inc., Sprott Securities Inc. and Jennings Capital Inc. (11/24)

Symbollon
Pharmaceuticals
Inc.
(OTC BB:
SYMBA)

Private placement of stock and warrants

1.26S and 0.63W

$0.63

Investors purchased Class A stock and warrants; each warrant is exercisable at $0.65 until Feb. 28, 2006; the investment also included $185,800 in prepaid services for manufacturing, consulting and clinical trial expenses (11/8)

Synthetic
Blood International Inc.
(OTC BB:SYBD)

Bridge financing

ND

ND

The company received funding from overseas investors that is expected to fund operations through the middle of 1Q:05 (11/11)

VaxGen Inc.
(OTC BB:VXGN)

Private placement of stock

3S

$40

VaxGen sold the shares at $13.25 each in a direct offering of unregistered securities to institutional investors; Punk, Ziegel & Co. and Trout Capital LLC were placement agents (11/22)

Viral Genetics
Inc.
(OTC BB:
VRAL)

Private placement of stock and warrants

8S and 4W

$2

The company sold 8M restricted shares; the warrants are exercisable at $1 per share until Nov. 17, 2006 (11/18)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

** = Item occurred in October but was not included in previous chart.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; VSE = Vancouver Stock Exchange.

No Comments